PRAGUE-26
A Multicentre, Randomized Trial of Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism (PRAGUE-26)
Patient / Population Intervention / Exposure Comparison Outcome
In 558 patients with intermediate–high-risk pulmonary embolism, catheter-directed thrombolysis was compared with anticoagulation alone on death, recurrent embolism or decompensation at 7 days.
N
558
Design
Investigator-initiated, academic, prospective, multicentre (eight Czech centres), open-label, 1:1 randomised, active-controlled, parallel-group phase 4 trial; primary endpoint at 7 days; functional and patient-reported outcomes and cost-effectiveness followed to 2 years
Endpoint
Clinical composite of all-cause mortality, recurrent PE (symptomatic, CTA-confirmed) or cardiorespiratory decompensation/collapse within 7 days of randomisation